

PENTHROX[®]
(METHOXYFLURANE)

1 NAME OF THE MEDICINAL PRODUCT

PENTHROX[®] 3 mL inhalation vapour, liquid

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each bottle contains 3 mL of methoxyflurane 99.9%.

3 PHARMACEUTICAL FORM

Inhalation vapour, liquid.

Clear, almost colourless, volatile liquid, with a characteristic fruity odour.

4 CLINICAL PARTICULARS

4.1 Indications

- Emergency relief of moderate to severe pain in conscious adult patients with trauma and associated pain.
- Short-term relief of moderate to severe acute pain, associated with interventional medical procedures, in monitored conscious adult patients.

See sections 4.2 and 5.1.

4.2 Posology and method of administration

PENTHROX[®] should be self-administered under supervision of a person trained in its administration, using the hand held PENTHROX[®] Inhaler.

One bottle of 3 mL PENTHROX[®] to be vaporised in a PENTHROX[®] inhaler. On finishing the 3 mL dose, another 3 mL may be used. Dose of PENTHROX[®] should not exceed 6 mL in a single administration. Administration on consecutive days is not recommended and the total dose to a patient in a week should not exceed 15 mL (see section 4.4).

Onset of pain relief is rapid and occurs after 6 – 10 inhalations. Patients should be instructed to inhale intermittently to achieve adequate analgesia. Patients are able to assess their own level of pain and titrate the amount of PENTHROX[®] inhaled for adequate pain control. With continuous inhalation, 3 mL PENTHROX[®] provides analgesic relief for up to 25-30 minutes. Intermittent inhalation may provide longer analgesic relief. Patients should be advised to take the lowest possible dose to achieve pain relief.

PENTHROX[®] should not be used in children under 18 years.


Method of Administration

Instructions on the preparation of the PENTHROX[®] Inhaler and correct administration are provided in the Figures below.

- 1 Ensure the optional Activated Carbon (AC) Chamber is inserted into the dilutor hole on the top of the PENTHROX[®] Inhaler.



- 2 Remove the cap of the bottle by hand. Alternatively, use the base of the PENTHROX[®] Inhaler to loosen the cap with a ½ turn. Separate the Inhaler from the bottle and remove the cap by hand.



- 3 Tilt the PENTHROX[®] Inhaler to a 45° angle and pour the total contents of one PENTHROX[®] bottle into the base of the Inhaler whilst rotating.



- 4 Place wrist loop over patient's wrist. Instruct patient to inhale through the mouthpiece of the PENTHROX[®] Inhaler to obtain analgesia. First few breaths should be gentle and then breathe normally through Inhaler.




- 5 Instruct patient to exhale into the PENTHROX[®] Inhaler so the exhaled vapour passes through the AC Chamber which adsorbs any exhaled methoxyflurane.



- 6 If stronger analgesia is required, instruct patient to cover dilutor hole on the Inhaler or AC chamber with finger during use.



- 7 Instruct patient to inhale intermittently to achieve adequate analgesia. Continuous inhalation will reduce duration of use. Minimum dose to achieve analgesia should be administered.



- 8 Replace cap onto PENTHROX[®] bottle. Place used PENTHROX[®] Inhaler and used bottle in sealed plastic bag and dispose of responsibly.



4.3 Contraindications

- Use as an anaesthetic agent.
- Hypersensitivity to PENTHROX[®], any fluorinated anaesthetic or to any of the ingredients listed in Section 6.1.
- Known genetic susceptibility to malignant hyperthermia or family history of severe drug reactions to inhaled anaesthetics.
- Patients who have a history of showing signs of liver damage after previous methoxyflurane use or halothane anaesthesia.
- Clinically significant renal impairment.
- Clinically evident cardiovascular instability.
- Clinically evident respiratory depression.
- Altered level of consciousness.

4.4 Special warnings and precautions for use

Renal disease

Methoxyflurane causes significant nephrotoxicity at high doses. Nephrotoxicity is also related to the rate of metabolism. Factors that increase the rate of metabolism such as drugs that induce hepatic enzymes can increase the risk of toxicity with methoxyflurane as well as sub-groups of people with genetic variations that may result in fast metaboliser status (see section 4.5).

Nephrotoxicity is thought to be associated with inorganic fluoride ions, a metabolic breakdown product. Methoxyflurane impairs renal function in a dose-related manner. The lowest effective dose of methoxyflurane should be administered, especially in the elderly or patients with other known risk factors of renal disease.

An observational study in 1236 patients with trauma pain treated with methoxyflurane found that renal events were less frequent than in 1101 patients treated with other analgesics for trauma associated pain (0.7% versus 2.6%, $p < 0.001$).

Liver disease

Methoxyflurane is metabolised in the liver, therefore increased exposures in patients with hepatic impairment can cause toxicity. It is advisable not to administer methoxyflurane to patients who have shown signs of liver damage, especially after previous methoxyflurane or halothane anaesthesia.

PENTHROX[®] should be used with care in patients with underlying hepatic conditions or with risks for hepatic dysfunction (such as enzyme inducers - see also section 4.5).

An observational study on patients with trauma pain did not find a significant difference in occurrence of hepatic events between 1236 patients treated with methoxyflurane and 1101 patients treated with other analgesics for trauma associated pain (1.6% versus 2.1%, $p = 0.442$).

Cardiovascular system depression / Use in elderly

Potential effects on blood pressure and heart rate are known class-effects of high dose methoxyflurane used in anaesthesia and other anaesthetics. They do not appear to be significant at the analgesic doses. There is no particular pattern to the patients' systolic BP levels after methoxyflurane administration as an analgesic across age groups. However, as the risk may potentially be increased for older people with hypotension and bradycardia, caution should be exercised in the elderly due to possible reduction in blood pressure.

Respiratory depression

Respiratory depression has been reported also from analgesic doses of methoxyflurane (section 4.8).

Respiration should be monitored due to the risk for respiratory depression and hypoxia.

Central nervous system effects

Secondary pharmacodynamic effects including potential CNS effects such as sedation, euphoria, amnesia, ability to concentrate, altered sensorimotor co-ordination and

change in mood are also known class-effects. Self-administration of methoxyflurane in analgesic doses will be limited by occurrence of CNS effects, such as sedation.

Whilst the possibility of CNS effects may be seen as a risk factor for potential abuse, reports of the latter are very rare in post marketing use.

Occupational exposure

Healthcare professionals who are regularly exposed to patients using PENTHROX[®] inhalers should be aware of any relevant occupational health and safety guidelines for the use of inhalational agents. To reduce occupational exposure to methoxyflurane, the PENTHROX[®] Inhaler should be used with the Activated Carbon (AC) Chamber. Patients should be instructed to exhale into the PENTHROX[®] Inhaler so the exhaled vapour passes through the AC Chamber which adsorbs exhaled methoxyflurane. Multiple use of PENTHROX[®] Inhaler without the AC Chamber creates additional risk. Elevation of liver enzymes, blood urea nitrogen and serum uric acid have been reported in exposed maternity ward staff in delivery wards when methoxyflurane was used in the past in obstetric patients at the time of labour and delivery. There have been reports of non-serious and transient reactions such as dizziness, headache, nausea or malaise, and reports of hypersensitivity reactions to methoxyflurane or other ingredients in healthcare professionals exposed to PENTHROX[®].

The derived maximum exposure limit (MEL) for methoxyflurane is 15 ppm expressed as an 8-hour time weighted average (8-hr TWA). The odour detection threshold for methoxyflurane ranges between 0.13 and 0.19 ppm which is well below the MEL. The exposure levels of medical staff involved in supervising the use of PENTHROX[®] in hospital emergency triage rooms during an 8-hour shift were measured. The measurements showed levels (0.017 ppm, range 0.008 to 0.736 ppm) significantly lower than the MEL of 15 ppm.

Frequent repeated use

Due to the limitations on the dose of PENTHROX[®] (maximum - 6 mL) and the duration of pain relief, PENTHROX[®] is not appropriate for providing relief of break-through pain/exacerbations in chronic pain conditions. PENTHROX[®] is also not appropriate for relief of trauma related pain in closely repeated episodes for the same patient.

Butylated hydroxytoluene

PENTHROX[®] contains butylated hydroxytoluene (E321). Butylated hydroxytoluene may cause local skin reactions (e.g. contact dermatitis), or irritation to the eyes and mucous membranes. See section 6.1.

4.5 Interaction with other medicinal products and other forms of interaction

The metabolism of methoxyflurane is mediated by the CYP 450 enzymes particularly CYP 2E1, CYP 2B6 and to some extent CYP 2A6. It is possible that enzyme inducers (such as alcohol or isoniazid for CYP 2E1 and phenobarbital or rifampicin for CYP 2A6 and carbamazepine, efavirenz, rifampicin or nevirapine for CYP 2B6) which increase the rate of methoxyflurane metabolism might increase its potential toxicity and they should be avoided concomitantly with methoxyflurane.

Concomitant use of PENTHROX[®] with CNS depressants e.g. opioids may produce

additive depressant effects. If opioids are given concomitantly with PENTHROX[®], the patient should be observed closely, as is normal clinical practice with opioids.

Concomitant use of methoxyflurane with medicines (e.g. antibiotics) which are known to have a nephrotoxic effect should be avoided as there may be an additive effect on nephrotoxicity. Antibiotics with known nephrotoxic potential include tetracycline, gentamicin, colistin, polymyxin B and amphotericin B. It is advisable to avoid using sevoflurane anaesthesia following methoxyflurane analgesia, as sevoflurane increases serum fluoride levels and nephrotoxicity of methoxyflurane is associated with raised serum fluoride.

4.6 Fertility, pregnancy and lactation

Fertility

No clinical data on effects of methoxyflurane on fertility are available. Limited data from animal studies do not indicate any effects on sperm morphology.

Pregnancy (Category C)

Data available from animal studies are insufficient with respect to reproductive toxicity (see section 5.3).

Where methoxyflurane has been used for obstetric analgesia in pregnant women, there has been a single report of neonatal respiratory depression associated with a high fetal level of methoxyflurane. However, when low concentrations were administered, or the duration of higher concentrations was kept short, per recommended posology, methoxyflurane was found to have little effect on the fetus. No fetal complications were reported to result from methoxyflurane analgesia in the mother in all the studies completed in obstetric analgesia.

A retrospective study examined the prevalence of in utero exposure and perinatal outcomes associated with methoxyflurane exposure during ambulance transport over a 17-year period. It was conducted using linked ambulance, emergency department, hospital, congenital anomaly and mortality data. First-trimester methoxyflurane exposure (n=270) was not associated with an increased risk of congenital anomalies compared to fentanyl (n=75) or no analgesic (n=1,620). Second-trimester (n=321) and third-trimester (n=403) methoxyflurane exposure was not associated with an increased risk of preterm birth, low birth weight or perinatal mortality compared with fentanyl (n=77 in second-trimester, n=33 in third-trimester) and no analgesic (n=2,556 in second-trimester, n=4,687 in third-trimester). Methoxyflurane administration on day of delivery (n=657) was also not associated with an increased risk of labour or delivery complications when compared to fentanyl (n=22) and no analgesic (n=2,667).

As with all medicines care should be exercised when administered during pregnancy especially the first trimester.

Breast-feeding

There is insufficient information on the excretion of methoxyflurane in human milk. Caution should be exercised when methoxyflurane is administered to a nursing mother.

4.7 Effects on ability to drive and use machines

Methoxyflurane may have a minor influence on the ability to drive and use machines. Dizziness, somnolence and drowsiness may occur following the administration of methoxyflurane (see section 4.8). A 15-minute inhalation of methoxyflurane in healthy volunteers induced an acute but short-lasting impairment of psychomotor and cognitive performance, which returns to normal within 30 minutes after cessation of inhalation.

Patients should be advised not to drive or operate machinery if they are feeling drowsy or dizzy.

4.8 Undesirable effects

Summary of safety profile

The most frequently observed non-serious reactions to PENTHROX[®] are CNS type reactions such as dizziness, and somnolence, and are generally easily reversible.

Serious dose-related nephrotoxicity has only been associated with methoxyflurane when used in large doses over prolonged periods during general anaesthesia. Methoxyflurane is therefore no longer used for anaesthesia. See section 4.4 under renal disease. The recommended maximum dose for PENTHROX[®] should therefore not be exceeded.

Liver injury may occur rarely (less than 1 case per 1,000 patients) and hepatic enzymes increased may occur uncommonly (less than 1 case per 100 patients) with analgesic use of methoxyflurane. See section 4.4 under liver disease.

Tabulated list of adverse reactions

The adverse drug reactions related to PENTHROX[®] observed in clinical studies and treatment-emergent events from postmarketing sources are listed in the table below, classified according to frequency (very common $\geq 1/10$; common $\geq 1/100$ to $< 1/10$; uncommon $\geq 1/1,000$ to $< 1/100$; rare $\geq 1/10,000$ to $< 1/1,000$; very rare $< 1/10,000$; and not known (cannot be estimated from the available data)).

MedDRA System Organ Class	Very Common ≥1/10	Common ≥1/100 to <1/10	Uncommon ≥1/1,000 to <1/100	Rare ≥1/10,000 to <1/1000	Unknown
Immune system disorders					Hypersensitivity [^]
Metabolism and nutrition disorders				Increased appetite	
Psychiatric disorders			Disturbance in attention Euphoric Mood	Anxiety Depression Inappropriate affect Verbigeration	Affect lability [^] Agitation [^] Confusional state [^] Dissociation [^] Restlessness [^]
Nervous system disorders		Dizziness Somnolence	Amnesia Dysarthria Dysgeusia Headache Paraesthesia	Peripheral sensory neuropathy	Altered state of consciousness [^] Nystagmus [^]
Eye disorders			Vision impairment		
Vascular disorders			Hypotension	Flushing Hypertension	
Respiratory, thoracic and mediastinal disorders			Cough		Choking [^] Hypoxia [^] Respiratory depression [^]
Gastrointestinal disorders			Dry mouth Nausea Oral discomfort Vomiting	Oral pruritus Salivary hypersecretion	
Hepatobiliary disorders				Liver injury	Hepatic failure [^] Hepatitis [^] Jaundice [^]
Skin and subcutaneous tissue disorders				Hyperhidrosis	
Renal and urinary disorders					Renal failure [^]
General disorders		Feeling drunk	Fatigue Feeling abnormal Feeling of relaxation	Chills	

Investigations			Hepatic enzyme increased		Blood uric acid increased^ Blood urea increased^ Blood creatinine increased^
----------------	--	--	--------------------------	--	--

^Other events linked to methoxyflurane use in analgesia found in post marketing experience and in scientific literature

4.9 Overdose

In the event of overdose, anaesthetic effects may occur with signs of excessive drowsiness, (including loss of consciousness), lowering of blood pressure, respiratory depression, pallor and muscle relaxation. After PENTHROX[®] discontinuation such overdose effects usually resolve quickly often with no other intervention required but cardiorespiratory supportive measures should be implemented if necessary.

High doses of methoxyflurane cause dose related nephrotoxicity. High output renal failure has occurred several hours or days after the administration of repeated high analgesic or anaesthetic doses of methoxyflurane.

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic Class: Analgesic

ATC code: N02BG09

Methoxyflurane vapour provides analgesia when inhaled at low concentrations. The precise mechanism of action whereby methoxyflurane produces analgesia at sub-anaesthetic doses is unknown, although a reduction in substance P and β -endorphine- like immunoreactivity in the brain has been suggested.

After methoxyflurane administration, drowsiness may occur. During methoxyflurane administration, the cardiac rhythm is usually regular. The myocardium is only minimally sensitised to adrenaline by methoxyflurane. At analgesic therapeutic doses pain relief may lead to some decrease in blood pressure. This may be accompanied by bradycardia.

Clinical efficacy and safety

The efficacy and safety of PENTHROX[®] was demonstrated in a clinical study in the treatment of acute pain in patients ≥ 12 years with minor trauma presenting to an Emergency Department. 300 patients were randomised in a 1:1 ratio to receive methoxyflurane or placebo. Patients with a pain score of ≥ 4 to ≤ 7 on the Numerical Rating Scale were eligible for the study. The mean pain scores (Visual Analogue Scale) observed at baseline were similar in the methoxyflurane (64.8) and placebo (64.0)

groups.

The primary efficacy variable, the estimated mean change in VAS pain from Baseline to 5 min, 10 min, 15 min and 20 min, was greater for the methoxyflurane group (-23.1, -28.9, -34.0 and -35.0 respectively) when compared to the placebo group (-11.3, -14.8, -15.5 and -19.0 respectively). Overall, there was a highly significant difference between the methoxyflurane and placebo group (estimated treatment effect -15.1; 95% CI -19.2 to -11.0; $p < 0.0001$). The greatest treatment effect was seen at 15 minutes (estimated treatment effect of -18.5).

An analysis was undertaken where a responder was defined as a patient who experienced at least a 30% improvement from baseline VAS pain score. Results of this analysis indicated that percentage of responders at 5, 10, 15 and 20 mins was significantly greater for the methoxyflurane group (51.0%, 57.7%, 63.8%, 63.8%) when compared to the placebo group (23.5%, 30.9%, 33.6%, 37.6%), with $p < 0.0001$ at each time-point. A total of 126 patients (84.6%) in the methoxyflurane group experienced their first pain relief after 1-10 inhalations in comparison to 76 patients (51%) in the placebo group.

5.2 Pharmacokinetic properties

Absorption

Methoxyflurane has the following partition coefficients:

- a water/gas coefficient of 4.5,
- a blood/gas coefficient of 13 and
- an oil/gas coefficient of 825

Methoxyflurane enters the lungs in the form of a vapour and is rapidly transported into the blood, therefore there is a rapid onset of analgesic action. In a pharmacokinetic (PK) study in healthy volunteers, the mean plasma concentration-time curves showed an extremely rapid rise in methoxyflurane plasma concentrations. Following a single dose of 3 mL methoxyflurane inhaled intermittently over an hour, the arterial profile is demonstrated by a t_{max} at 0.25 hours (range 0.08 – 0.75 hours), C_{max} of 32.39 ug/mL (SD 13.546 ug/mL, CV 41.8%) and the AUC of 28.95 h.ug/mL (range 12.3-52.6 h.ug/mL).

Distribution

Methoxyflurane has a high oil/gas coefficient hence methoxyflurane is highly lipophilic. Methoxyflurane has great propensity to diffuse into fatty tissues where it forms a reservoir from which it is released slowly over days.

Biotransformation

Biotransformation of methoxyflurane occurs in man. Methoxyflurane is metabolised by dechlorination and o-demethylation in the liver, mediated by CYP 450 enzymes particularly CYP 2E1, CYP 2B6 and CYP 2A6. Methoxyflurane is metabolised to free fluoride, oxalic acid, difluoromethoxyacetic acid, and dichloroacetic acid. Both free fluoride and oxalic acid can cause renal damage at concentrations higher than those achievable with single analgesic dose use. Methoxyflurane is more susceptible to metabolism than other halogenated methyl ethyl ethers and has greater propensity to diffuse into fatty tissues. Hence methoxyflurane is released slowly from this reservoir and becomes available for biotransformation for many days.

Elimination

In the PK study in healthy volunteers who inhaled 3 mL of methoxyflurane over 1 hour, there was an early peak in methoxyflurane plasma concentration-time curves followed by a rapid elimination from the plasma, with methoxyflurane concentrations returning to baseline by 24 hours after administration. Concentrations of the metabolite, inorganic fluoride, rose less quickly than methoxyflurane (median t_{max} of 1.5 hours) and were gradually eliminated from the plasma, with significant concentrations measured in plasma 48 hours after methoxyflurane administration. Following a single dose of 3 mL methoxyflurane inhaled intermittently over an hour, the venous median half-life for methoxyflurane is 3.16 hours (range 1.06-7.89 hours), and that for inorganic fluoride is 33.30 hours (range 23.50-51.20 hours). The PK profiles for methoxyflurane and inorganic fluoride exhibited high inter-subject variability.

Approximately 60% of methoxyflurane uptake is excreted in the urine as organic fluorine, fluoride and oxalic acid; the remainder is exhaled unaltered or as carbon dioxide. Higher peak blood fluoride levels may be obtained earlier in obese than in non-obese people, and in the elderly.

5.3 Preclinical safety data

Genotoxicity and carcinogenicity

Methoxyflurane is not considered mutagenic as indicated in an *in vitro* Ames study and an *in vivo* micronucleus study in rats.

There is no evidence that methoxyflurane has carcinogenic properties.

Reproductive and developmental toxicity

Methoxyflurane does not affect sperm cells in mice. In studies in mice and rats, methoxyflurane crossed the placenta but demonstrated no evidence of embryotoxic or teratogenic properties. However, delayed fetal development (reduced fetal body weight and decreased ossification) was observed following repeated dosing over 9 days. The no observed adverse effect level (NOAEL) for embryo-fetal development was 0.006% (104 mg/kg) - 4h/day in mice and close to 0.01% (245 mg/kg) - 8 h/day in rats. The NOAELs in mouse and rat represent a 1- to 2-fold margin on a mg/kg basis and a 0.1- to 0.3-fold margin on a mg/m² basis versus the proposed maximum clinical dose. As PENTHROX[®] is not intended for daily use, the risk of delayed fetal development is considered to be very low.

Renal and hepatic effects

Continuous administration of higher anaesthetic doses of methoxyflurane to rats has been associated with renal tubular necrosis and mitochondrial swelling. Repeated intermittent or continuous administration of subanaesthetic concentrations of methoxyflurane has been associated with limited and commonly reversible hepatic changes (fatty metamorphosis, elevated ALT/AST) in several species.

After 6 hours of continuous inhalation of methoxyflurane for 14 consecutive days in rats, kidney findings were limited to minimal vacuolation of cortical tubules and in the liver, there was minimal/mild centrilobular vacuolation expansion of cytoplasm (centrilobular hepatocytes) lending the cytoplasm a frothy appearance.

After 90 minutes of continuous inhalation of methoxyflurane for 14 consecutive days in dogs, no salient kidney findings were noted and in the liver, there was minimal/mild

centrilobular glycogen accumulation.

NOAELs of 396 mg/kg and 153 mg/kg were reported for the above rat and dog studies respectively. These renal and hepatic effects were however seen with prolonged and repeat administrations over 14 days therefore the total exposures are in excess of those anticipated through normal clinical use of the product.

6 PHARMACEUTICAL PARTICULARS

6.1 Other ingredients

Butylated hydroxytoluene E321.

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

Please refer to outer box.

6.4 Special precautions for storage

Store below 30°C.

6.5 Nature and contents of container

PENTHROX[®] may be supplied in the following presentations:

- a) 3 mL sealed bottle with a tear off tamper seal (pack of 10)
- b) Combination pack with one 3 mL sealed bottle and one PENTHROX[®] Inhaler (pack of 10) without Activated Carbon (AC) Chamber
- c) Combination pack with one 3 mL sealed bottle and one PENTHROX[®] Inhaler with AC Chamber (pack of 1)

Not all pack sizes may be marketed.

6.6 Special precautions for disposal of a used medicinal product

After loading the PENTHROX[®] Inhaler, replace cap onto PENTHROX[®] bottle. After use, place used PENTHROX[®] Inhaler and used bottle in a plastic bag, seal and dispose of responsibly.

7 MARKETING AUTHORISATION HOLDER

Manufactured by:

Medical Developments International Limited, Victoria, Australia

Imported by:

DAIICHI SANKYO (THAILAND) LTD.

24th Fl., United Center Bldg.,
323, Silom Rd., Silom, Bangrak, Bangkok, 10500, Thailand
Tel.: +66 2631-2070-9 FAX: +66 2236-2656

8 MARKETING AUTHORISATION NUMBER(S)

1C 15075/63 (NC)

**9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE
AUTHORISATION**

9 April 2020

10 DATE OF REVISION OF THE TEXT

Oct 2025